Docteur Cédric SZTEJKOWSKI

Bibliographie

• Combining ts- and a bDMARD in refractory rheumatoid arthritis: an unusual adverse event

  2024

  ArticleRheumatology

• Biais Cognitifs En Rhumatologie

  2023

  ArticleRevue du Rhumatisme

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• HOPITAL LOUIS PASTEUR

  39 Avenue DE LA LIBERTE, 68024 Colmar

  ☎ 0389124000Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (1)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• Santé. La fac de médecine délocalise deux chercheurs à Colmar - DNA

  📰 DNA · 17/01/2025

  <a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOMjdacVU1bjVqLWRIa3ZDd2RvczlhYkhYaG1BMFRoY0NWbEJWMzNVU1dfaFhYMWJaNGFYb1ZoSjJvMzVOTHVjY3k0R0VzbEdrdS1pbk9mQTRPWlJwTVNTWHBPZnNMVUFBRUtLMWJldHpnTlhCT0dnUUYwZlFmYzdPMGhUMnBnR0I5VjNBZ19reGMzUjhhVl85cVFB?oc=5" target="_blank">Santé. La fac de mé

Top publications · les plus citées

• 1

  Treatment of relapsing polychondritis: a systematic review

  Clinical and experimental rheumatology · 2022

  📚 29 citations🎯 RCR 3.74Top 12% NIH🔓 Open Access📄 PDF gratuit ↗
• 2

  The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials

  RMD open · 2023

  📚 16 citations🎯 RCR 1.90🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Objectives The objective of this systematic review was to provide an overview of current developments and potentially available therapeutic options for spondyloarthritis (SpA) in the coming years. Methods We conducted a systematic review of 17 national and international clinical trial databases for all disease-modifying antirheumatic drugs (DMARDs) for SpA that are already marketed, in clinical development or withdrawn. The search was performed on February 2023 with the keywords “spondyloarthritis”, “ankylosing spondylitis” and “psoriatic arthritis”. For each molecule, we only considered the study at the most advanced stage of clinical development. Results Concerning axial SpA (axSpA), a total of 44 DMARDs were identified: 6 conventional synthetic DMARDs (csDMARDs), 27 biological DMARDs (bDMARDs) and 11 targeted synthetic DMARDs (tsDMARDs). Among the 18 targeted treatments (b+tsDMARDs) in current development, corresponding trials reached phase I (n=1), II (n=10) and III (n=7). Ten molecules are IL-17 inhibitors, two Janus kinase (JAK) inhibitors and two granulocyte-macrophage colony-stimulating factor inhibitors; four have another mode of action. Concerning psoriatic arthritis (PsA), 44 DMARDs were identified: 5 csDMARDs, 27 bDMARDs and 12 tsDMARDs. Among the 15 molecules in current development, corresponding trials reached phase II (n=8) and III (n=7). Six molecules are JAK inhibitors, six IL-17 inhibitors and one an IL-23 inhibitor; two have another mode of action. Conclusion This systematic review identified 18 and 15 molecules in clinical development for axSpA and PsA, respectively, which suggests a strengthening of the therapeutic arsenal in the coming years. However, with so many DMARDs but low target diversity, we will need to develop strategies or biomarkers to help clinicians make informed treatment decisions.

• 3

  European Reference Network (ERN) ReCONNET methodology for the cross-cultural adaptation of instruments for research and care in the context of rare connective tissue diseases (CROSSADAPT)

  Orphanet journal of rare diseases · 2025

  📚 3 citations🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract The traditional process of intercultural adaptation, while suitable for one or a few target languages, is not optimal for developing instruments for rare connective tissue diseases (CTDs) in multiple languages simultaneously. The European Reference Network ReCONNET presents the protocol for a novel methodology for cross-cultural adaptation of instruments for research and care in the context of rare CTDs (ReCONNET-CROSSADAPT). It is initiated by the identification of ‘key-terms’ that are crucial for maintaining the original meaning of the source document. Each language group, led by a senior member and two collaborators, independently assesses the existence and equivalence of these key terms in target languages. Reconciliation meetings are held to establish agreed-upon terms for consistent usage across translations when difficulties arise with key-terms. Subsequently, each language group translates the source document, followed by a reconciliation meeting involving one CTD patient in each group. The purpose of this meeting is to address potential discrepancies among translations, ensuring a comprehensive assessment from a linguistic, cultural and patient perspective. Collective feedback and consensus-based decision-making guide the resolution process. This methodology eliminates the need for backward translation, optimizing time and cost utilization. This new ReCONNET-CROSSADAPT methodology ensures linguistic accuracy, cultural relevance, and contextual appropriateness for the cross-cultural adaptation of instruments for research and care in the context of rare CTDs.

Publications scientifiques (5) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche